Literature DB >> 19879427

Conclusions and perspectives.

Saverio Bettuzzi1.   

Abstract

Since its first discovery, CLU has been fascinating many researchers around the world, probably because CLU has always been a surprise. In many studies, CLU showed up unexpected as a secondary but significant observation in the hands of scientists which probably had no specific intention to study it. Too often the first descriptions of the structure, action, and biological meaning of CLU had to be changed in the light of novel and rather surprising findings, making what was thought to be well established, actually obsolete. CLU is a biological object still in movement. To understand more, we will have to cope correctly with this challenge. As an Ariadne's thread, following CLU we will challenge our static ideas pointing to alternative views which will possibly lead us to a different thinking and a much better understanding of the complexity of cell transformation. In this final chapter, we will provide "take home messages" from the chapters of vols. 104 and 105 concerning the most up to date knowledge about CLU. Then we will provide some agreements and consensus in this field, wherever possible. Highlighting possible faults or misunderstandings, we will define the open issues which will very likely drive the research on CLU in the near future. Finally, we will address how this novel knowledge about CLU may possibly result in important implementations, from basic science all the way to the clinical setting, in the fight against cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19879427     DOI: 10.1016/S0065-230X(09)05008-8

Source DB:  PubMed          Journal:  Adv Cancer Res        ISSN: 0065-230X            Impact factor:   6.242


  5 in total

1.  Circulating clusterin (apolipoprotein J) levels do not have any day/night variability and are positively associated with total and LDL cholesterol levels in young healthy individuals.

Authors:  Konstantinos N Aronis; Maria T Vamvini; John P Chamberland; Christos S Mantzoros
Journal:  J Clin Endocrinol Metab       Date:  2011-09-07       Impact factor: 5.958

2.  Plasma Clusterin and Lipid Profile: A Link with Aging and Cardiovascular Diseases in a Population with a Consistent Number of Centenarians.

Authors:  Angela Baralla; Elisabetta Sotgiu; Marta Deiana; Sara Pasella; Sara Pinna; Andrea Mannu; Elisabetta Canu; Giovanni Sotgiu; Antonello Ganau; Angelo Zinellu; Salvatore Sotgia; Ciriaco Carru; Luca Deiana
Journal:  PLoS One       Date:  2015-06-15       Impact factor: 3.240

Review 3.  Clusterin and Its Role in Insulin Resistance and the Cardiometabolic Syndrome.

Authors:  Jennifer Wittwer; David Bradley
Journal:  Front Immunol       Date:  2021-02-25       Impact factor: 7.561

Review 4.  The Functional Role of Lipoproteins in Atherosclerosis: Novel Directions for Diagnosis and Targeting Therapy.

Authors:  Yongzheng Lu; Xiaolin Cui; Li Zhang; Xu Wang; Yanyan Xu; Zhen Qin; Gangqiong Liu; Qiguang Wang; Kang Tian; Khoon S Lim; Chris J Charles; Jinying Zhang; Junnan Tang
Journal:  Aging Dis       Date:  2022-04-01       Impact factor: 6.745

Review 5.  Apolipoprotein J: A New Predictor and Therapeutic Target in Cardiovascular Disease?

Authors:  Ning Yang; Qin Qin
Journal:  Chin Med J (Engl)       Date:  2015-09-20       Impact factor: 2.628

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.